Xian-Yang Qin, Yohei Shirakami, Masao Honda, Shiou-Hwei Yeh, Kazushi Numata, Ya-Yun Lai, Chiao-Ling Li, Feifei Wei, Yali Xu, Kenji Imai, Koji Takai, Makoto Chuma, Nagisa Komatsu, Yutaka Furutani, Luc Gailhouste, Hiroshi Aikata, Kazuaki Chayama, Masaru Enomoto, Ryosuke Tateishi, Kazunori Kawaguchi, Tatsuya Yamashita, Shuichi Kaneko, Katsuya Nagaoka, Motohiko Tanaka, Yutaka Sasaki, Yasuhito Tanaka, Hideo Baba, Kouichi Miura, Sae Ochi, Takahiro Masaki, Soichi Kojima, Tomokazu Matsuura, Masahito Shimizu, Pei-Jer Chen, Hisataka Moriwaki, Harukazu Suzuki
The proto-oncogene MYCN expression marked a cancer stem-like cell population in hepatocellular carcinoma (HCC) and served as a therapeutic target of acyclic retinoid (ACR), an orally administered vitamin A derivative that has demonstrated promising efficacy and safety in reducing HCC recurrence. This study investigated the role of MYCN as a predictive biomarker for therapeutic response to ACR and prognosis of HCC. MYCN gene expression in HCC was analyzed in the Cancer Genome Atlas and a Taiwanese cohort (N = 118)...
February 21, 2024: International Journal of Cancer. Journal International du Cancer